

ADAKVEO (CRIZANLIZUMAB)

INFUSION ORDERS

FAX: 470.922.3656 | **PHONE:** 470.377.6400

PATIENT INF	ORMATION:	Fax completed form, in	surance information, and clinical documentation to 470.922.3656	
	OrtimAtrioit.		_ DOB: Phone:	
Patient Status:	☐ New to Therapy	☐ Continuing Therapy	Next Treatment Date:	
INSURANCE	INFORMATION:	Please attach a copy	of insurance cards (front and back)	
MEDICAL INI				
Diagnosis:	☐ Sickle cell dis	ease		
J				
ICD-10 code:				
		ired) Allergies:		
		, 0		
THERAPY OF	RDER			
Adakveo:				
□Initial start:	5ma/ka IV on wee	ek 0 and 2, then ever	y 4 weeks thereafter x 1 year	
	omgrig ir on not	,	,	
□Maintenand	ce Dosing: 5mg/k	g IV every 4 weeks	x 1 year	
Additional or	ders:			
, taaitional of	dolo			
Lab orders: _			Lab frequency:	
Anaphylaetia Da	action Ordova (home)	ootionto):		
	action Orders (home p	•		
• Epinephrine	(based on patient wei	ight):	or subQ; may repeat in 5-10 minutes x1	
Epinephrine>30kg (>66lb)	(based on patient we os): EpiPen 0.3mg or	ight): compounded syringe IM	or subQ; may repeat in 5-10 minutes x1 ringe IM or subQ; may repeat in 5-10 minutes x1	
Epinephrine>30kg (>66lb15-30kg (33-	(based on patient webs): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1	ight): compounded syringe IM		
Epinephrine>30kg (>66lb15-30kg (33-Diphenhydra	(based on patient wei os): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5	ight): compounded syringe IM 5mg or compounded sy	ringe IM or subQ; may repeat in 5-10 minutes x1	
Epinephrine>30kg (>66lb15-30kg (33-Diphenhydra	(based on patient wei os): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult)	ringe IM or subQ; may repeat in 5-10 minutes x1	
Epinephrine>30kg (>66lb15-30kg (33-Diphenhydra	(based on patient wei os): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult)	ringe IM or subQ; may repeat in 5-10 minutes x1	
Epinephrine>30kg (>66lb15-30kg (33-DiphenhydraRefer to phys	(based on patient wei os): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult)	ringe IM or subQ; may repeat in 5-10 minutes x1	
 Epinephrine >30kg (>66lb 15-30kg (33- Diphenhydra Refer to phys PROVIDER IN By signing this form and utility	(based on patient weins): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5 sician order or institut	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult) ional protocol for pediatr	ringe IM or subQ; may repeat in 5-10 minutes x1 ic dosing as applicable o serve as your prior authorization and specialty pharmacy designated	
 Epinephrine >30kg (>66lb 15-30kg (33- Diphenhydra Refer to phys PROVIDER IN By signing this form and utiliagent in dealing with medical agent in dealing with a dealing with a dealing with a dealing with a deali	(based on patient weigs): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5 sician order or institut	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult) ional protocol for pediatr	ringe IM or subQ; may repeat in 5-10 minutes x1 ic dosing as applicable o serve as your prior authorization and specialty pharmacy designated care for the patient.	
 Epinephrine >30kg (>66lb 15-30kg (33- Diphenhydra Refer to phys PROVIDER IN By signing this form and utiliagent in dealing with medical provider Name:Provider NPI:	(based on patient weigs): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-5 sician order or institut NFORMATION zing our services, you are authorizing and prescription insurance compa	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult) ional protocol for pediatr or Biocare Infusion, and its employees to the preferred site of the compounded syring signature:	ringe IM or subQ; may repeat in 5-10 minutes x1 ic dosing as applicable o serve as your prior authorization and specialty pharmacy designated hare for the patient. Date: Contact Person:	
 Epinephrine >30kg (>66lb 15-30kg (33- Diphenhydra Refer to phys PROVIDER IN By signing this form and utiliagent in dealing with medical provider Name:Provider NPI:	(based on patient weiges): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-8 sician order or institut NFORMATION zing our services, you are authorizing and prescription insurance companies are Infusion selecting care Infusion selecting	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult) ional protocol for pediatr or Biocare Infusion, and its employees to the preferred site of the compounded syring signature:	ringe IM or subQ; may repeat in 5-10 minutes x1 ic dosing as applicable o serve as your prior authorization and specialty pharmacy designated care for the patient.	
 Epinephrine >30kg (>66lb 15-30kg (33- Diphenhydra Refer to phys PROVIDER IN By signing this form and utiliagent in dealing with medical provider Name:Provider NPI:	(based on patient weiges): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-8 sician order or institut NFORMATION zing our services, you are authorizing and prescription insurance companies are Infusion selecting care Infusion selecting	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult) ional protocol for pediatr or Biocare Infusion, and its employees to the preferred site of the compounded syring signature:	ringe IM or subQ; may repeat in 5-10 minutes x1 ic dosing as applicable o serve as your prior authorization and specialty pharmacy designated hare for the patient. Date: Contact Person:	
 Epinephrine >30kg (>66lb 15-30kg (33- Diphenhydra Refer to phys PROVIDER IN By signing this form and utiliagent in dealing with medical provider Name:Provider NPI:	(based on patient weighs): EpiPen 0.3mg or 66lbs): EpiPen Jr. 0.1 mine: Administer 25-8 sician order or institut NFORMATION zing our services, you are authorizing and prescription insurance compatient of the companient of the	ight): compounded syringe IM 5mg or compounded sy 50mg PO or IV (adult) ional protocol for pediatr or Biocare Infusion, and its employees to the preferred site of the compounded syring signature:	ringe IM or subQ; may repeat in 5-10 minutes x1 ic dosing as applicable o serve as your prior authorization and specialty pharmacy designated hare for the patient. Date: Contact Person:	



COMPREHENSIVE SUPPORT FOR

ADAKVEO THERAPY

PATIENT INFO	ORMATION:	
Patient Name:		DOB:
REQUIRED DO	OCUMENTATION FOR REFERRAL PROCESSING & IN	SURANCE APPROVAL
☐ Include sign	ned and completed order (MD/prescriber to complete pag	le 1)
☐ Include pa	atient demographic information and insurance information	
Include pa	atient's medication list	
☐ Supportin	ng clinical notes (H&P) to support primary diagnosis - Incl	uding:
	es the patient have a history of 2 or more sickle cell-related in the previous 12 months? \Box Yes \Box No	d vaso-occlusive crises
☐ Is the pa	atient currently receiving hydroxyurea therapy?	
	e patient have a history of treatment failure, intolerance, o oxyurea therapy? ☐ Yes ☐ No	r contraindication
Other me	edical necessity:	

Biocare Infusion will complete insurance verification and submitall required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance